【摘要】 目的探讨血清肿瘤标志物CA19-9、CA242和CA50单项检测及联合检测在胰腺癌诊断中的应用价值。方法选取胰腺癌患者59例(胰腺癌组)、胰腺良性疾病患者64例(胰腺良性疾病组),采用直接化学发光方法对患者血清中CA19-9、CA242、CA50水平进行检测,并比较分析单一肿瘤标志物检测及联合检测的的诊断价值。结果胰腺癌患者血清CA19-9、CA242、CA50水平显著高于胰腺良性疾病组(P<0.05),肿瘤标志物单项检测,CA19-9敏感性最高(81.36%),CA242特异性最高(84.78%),联合检测可提高检测的敏感性(平行试验联合检测)和特异性(系列试验联合检测)。结论 CA19-9、CA242、CA50的联合检测对胰腺癌的诊断提供重要参考依据,具有较高的临床价值。更多还原

【Abstract】 Objective To investigate the value of combined detection of tumor markers CA19-9,CA242 and CA50 in diagnosis of pancreatic carcinoma. Methods The serum levels of CA19-9,CA242 and CA50 was detected by chemiluminescence immunoassay( CLIA) in 59 patients with pancreatic cancer( pancreatic cancer group),64 patients with benign pancreatic disease( benign pancreatic disease group). The diagnosis value of single and combined detection were compared and analyzed. Results The levels of serum CA19-9,CA242 and CA50 in pancreatic cancer group were significantly higher than those of benign pancreatic disease group( P <0. 05). The sensitivity of CA19-9( 81. 36%) was the highest,the specificity of CA242( 84. 78%) was the highest. The combined detection of CA19-9,CA242 and CA50 increased the sensitivity( parallel combined detection) and specificity( serial combined detection). Conclusion Combined detection of CA19-9,CA242 and CA50 could provide important clinical significance in the diagnosis of pancreatic cancer.更多还原